Nathan Weinstein
Stock Analyst at Aegis Capital
(0.28)
# 4,119
Out of 4,851 analysts
61
Total ratings
13.33%
Success rate
-26.12%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
EVGN Evogene | Maintains: Buy | $100 → $80 | $1.11 | +7,107.21% | 2 | Sep 12, 2022 | |
DRIO DarioHealth | Maintains: Buy | $20 → $15 | $0.70 | +2,055.17% | 6 | Aug 18, 2022 | |
VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.57 | +951.89% | 5 | Aug 15, 2022 | |
IMUX Immunic | Maintains: Buy | $40 → $35 | $0.78 | +4,416.13% | 2 | Aug 8, 2022 | |
STXS Stereotaxis | Initiates: Buy | $6 | $2.29 | +162.01% | 1 | Jul 12, 2022 | |
ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.29 | +1,212.91% | 5 | May 16, 2022 | |
TRVI Trevi Therapeutics | Initiates: Buy | $10 | $6.58 | +51.98% | 1 | Mar 29, 2022 | |
MDWD MediWound | Maintains: Buy | $63 → $49 | $21.68 | +126.07% | 4 | Mar 21, 2022 | |
ENVB Enveric Biosciences | Downgrades: Hold | $5,250 → $150 | $1.29 | +11,527.91% | 2 | Mar 8, 2022 | |
CING Cingulate | Initiates: Buy | $2,160 | $4.24 | +50,843.40% | 1 | Jan 11, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $1.35 | +2,129.16% | 1 | Dec 7, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $0.60 | +1,569.45% | 2 | Nov 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $24.05 | +565.28% | 2 | Sep 22, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $25.00 | +124.00% | 2 | Sep 9, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $2.47 | +993.12% | 3 | Aug 17, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.94 | +3,627.37% | 4 | Jun 7, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.05 | +485.37% | 1 | Mar 22, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $9.34 | +703.00% | 1 | Jan 26, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $3.11 | +2,726.67% | 3 | Oct 19, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $2.39 | +7,431.38% | 1 | Oct 8, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $4.36 | +2,996.33% | 3 | Aug 3, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $6.75 | +107.41% | 1 | Jul 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $11.85 | +1,757.32% | 7 | May 4, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $2.79 | +204.66% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.11
Upside: +7,107.21%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $20 → $15
Current: $0.70
Upside: +2,055.17%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.57
Upside: +951.89%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.78
Upside: +4,416.13%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.29
Upside: +1,212.91%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $6.58
Upside: +51.98%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $21.68
Upside: +126.07%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $5,250 → $150
Current: $1.29
Upside: +11,527.91%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $4.24
Upside: +50,843.40%
Dec 7, 2021
Initiates: Buy
Price Target: $30
Current: $1.35
Upside: +2,129.16%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $0.60
Upside: +1,569.45%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $24.05
Upside: +565.28%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $25.00
Upside: +124.00%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $2.47
Upside: +993.12%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.94
Upside: +3,627.37%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $2.05
Upside: +485.37%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $9.34
Upside: +703.00%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $3.11
Upside: +2,726.67%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $2.39
Upside: +7,431.38%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $4.36
Upside: +2,996.33%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $6.75
Upside: +107.41%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $11.85
Upside: +1,757.32%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $2.79
Upside: +204.66%